Please login to the form below
polycystic kidney disease
This page shows the latest polycystic kidney disease news and features for those working in and with pharma, biotech and healthcare.
Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka
Otsuka gains European nod for Jinarc extension. The European Commission has approved a label extension for Jinarc (tolvaptan) to include adult patients with CKD stage 4 Autosomal Dominant Polycystic Kidney Disease ... Jinarc is the only drug treatment
Latest news
-
Daily Brief: EU agencies brace for No Deal Brexit, GSK mulls spin-off, Realta scores in CKD
Reata Pharma success in kidney disease treatment. Reata Pharmaceuticals has produced phase II results showing its bardoxolone methyl (bardoxolone) can prevent or dealy kidney failure in a rare form of chronic ... the Phoenix trial in the autosomal
-
Otsuka finally gets FDA OK for kidney disease drug
polycystic kidney disease. ... to progression of kidney disease (measured using creatinine levels) and symptoms such as kidney pain and hypertension.
-
After some big setbacks, Sanofi talks up its R&D portfolio
Sanofi is highlighting half a dozen phase IIII programmes in the update, including dupilumab as a treatment for chronic obstructive pulmonary disease (COPD), oral GCS inhibitor venglustat for polycystic kidney disease,
-
AZ, BMS and Boehringer among UK Prix Galien finalists
tolvaptan. Jinarc. Otsuka. Polycystic kidney disease. nintedanib. Ofev. Boehringer Ingelheim. Idiopathic pulmonary fibrosis. ... Pompe Disease. azacitidine. Vidaza. Celgene. Myslodysplastic Syndrome. omalizumab. Xolair. Novartis. Sever persistent
-
New cancer meds and drug extensions top CHMP recommendations
The CHMP, the drug safety and efficacy arm of the EMA, has recommended approval for Otsuka's Jinarc (tolvaptan) for the treatment of patients with autosomal dominant polycystic kidney disease (ADPKD), ... This includes Adenuric, blockbuster oncology
More from news
Approximately 2 fully matching, plus 11 partially matching documents found.
Latest from PMHub
-
Making good practice common practice in rare disease
However, fatigue scores can’t be explained purely by disease activity and depression. ... 2015 - 88% of people with early-stage autosomal dominant polycystic kidney disease (ADPKD), reported physical symptoms including pain and general malaise.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- Amgen reports positive results for Otezla in psoriatic arthritis
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Seqera Labs and Genomics England partner to progress genomic research
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s RSV vaccine approved by FDA for older adults
No results were found
PMHub
Videum Health
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...
Latest intelligence
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
- Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
- Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...
